Global Respiratory Drugs Market 2018-2024
- March, 2018
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. The conditions included are acute respiratory distress syndrome, sarcoidosis of the lungs, asthma, chronic obstructive pulmonary disease, lung cancer, occupational lung disease, pulmonary hypertension, tuberculosis, cystic fibrosis, interstitial lung disease, lung transplants, and severe acute respiratory syndrome. The intensity of competition in the respiratory drug market is high with few players dominating the market. The heavy investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.
Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory drugs classes available in the market. Currently, the combination drugs are mainly driving the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will stimulate the market growth.
The “Global Respiratory Drugs Market” is estimated to witness a CAGR of 5.9% during the forecast period 2018-2024. The respiratory drugs market is analyzed based on two segments – Applications and Regions.
The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global respiratory drugs market, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by North America, with the US being the major contributor to the market growth.
Respiratory drugs find its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is a major market share holder currently. However, cystic fibrosis is anticipated to be the fastest growing segment in the market bacause of increased research & development and drug approval process related to it.
Novartis AG, GlaxoSmithKline plc, Astra Zeneca PLC., F. Hoffmann-La Roche Ltd, and Vertex Pharmaceuticals Inc are the key players in the market. Mylan, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Gilead Sciences, Inc, Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck & Co., Sanofi, and Mallinckrodt plc are some of the other prominent respiratory drugs manufacturers in the market.
Business partnerships, merger & acquisitions and a multifaceted pipeline are the major strategies of the market players. In March 2017, AstraZeneca and SenzaGen collaborated to develop genomic methods for respiratory allergens. In December 2016, Novartis out-licensed its three COPD products Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler to Sunovion Pharmaceuticals. In March 2017, Sanofi invested $147 million in AstraZeneca’s drug for preventing respiratory syncytial virus (RSV) infections. This gave equal share in costs and profits for both the companies.
In 2017, GSK became the leader in the market accounting for 25.6% of the market revenue. Vertex Pharma is one the biggest companies in this domain with the fastest growth rate in recent years due to its novel portfolio for Cystic Fibrosis and potential molecules in the clinical pipeline.
The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can find out about the major trends, drivers, investments, and vertical players’ initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives a detailed account of the key business opportunities to the prominent stakeholders to expand their businesses and capture the revenue in the specific verticals. It will help them to analyze the market before investing or expanding the business in this market.
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Importance of Respiratory Care
3.4 Trends of Respiratory Drugs Market
3.5 Related Markets
3.5.1 Oncology (Cancer) Drugs
3.5.2 Active pharmaceutical ingredients (APIs)
3.5.3 Over the counter drugs (OTC)
3.5.4 Diabetes Drugs
4 Market Outline
4.1 Pipeline Products of Respiratory Drugs by Major Companies
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics of Respiratory Drugs Market
126.96.36.199 Increasing Aging Population
188.8.131.52 Rising prevalence of respiratory diseases
184.108.40.206 High prevalence of tobacco smoking
220.127.116.11 Supportive initiatives from government and other organizations
18.104.22.168 Huge pool of undiagnosed chronic obstructive pulmonary disease population
22.214.171.124 Expiry of patents for blockbuster drugs
126.96.36.199 Complex drug development process
5.1.4 DRO – Impact Analysis
5.1.5 Key Stakeholders
6 Application: Market Size and Analysis
6.3 Chronic Obstructive Pulmonary Disease (COPD)
6.4 Cystic Fibrosis
6.5 Allergic Rhinitis
7 Regions: Market Size and Analysis
7.2 North America
7.2.2 United States
7.3.2 United Kingdom
7.5 Rest of the World
7.5.2 Middle East
8 Competitive Landscape
9 Vendor Profiles
9.1 Novartis AG
9.1.2 Business Unit
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 GlaxoSmithKline plc
9.2.2 Geographic Presence
9.2.3 Business Focus
9.2.4 SWOT Analysis
9.2.5 Business Strategy
9.3 Astra Zenca PLC
9.3.2 Geographic Presence
9.3.3 Business Focus
9.3.4 SWOT Analysis
9.3.5 Business Strategy
9.4 F.Hoffmann-La Roche Ltd.
9.4.2 Business Unit
9.4.3 Geographic Presence
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategy
9.5 Vertex Pharmaceuticals Inc.
9.5.2 Geographic Presence
9.5.3 Business Focus
9.5.4 SWOT Analysis
9.5.5 Business Strategy
10 Companies to Watch For
10.1 Boehringer Ingelheim GmbH
10.2 Teva Pharmaceutical Industries Ltd.
10.3 Gilead Sciences Inc.
10.4 Bayer AG
10.5 Pfizer Inc.
10.6 Bristol-Myers Squibb Co.
10.7 Merck & Co.
10.9 Mallinckrodt plc
TABLE 1 RESPIRATORY DRUGS: PIPELINE PRODUCTS 20
TABLE 2 PATENT EXPIRATION OF RESPIRATORY DRUGS 28
TABLE 3 RESPIRATORY DRUGS MARKET REVENUE BY APPLICATION, 2017–2024 ($MILLION) 31
TABLE 4 RESPIRATORY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 39
TABLE 5 MAJOR RESPIRATORY DRUGS MARKET ($MILLION) 49
TABLE 6 NOVARTIS AG: OFFERINGS 51
TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS 52
TABLE 8 NOVARTIS AG RESPIRATORY DRUGS PIPELINE MOLECULES 56
TABLE 9 GLAXOSMITHKLINE PLC: OFFERINGS 58
TABLE 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 59
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 66
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 68
TABLE 13 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 73
TABLE 14 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 74
TABLE 15 ROCHE: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT 78
TABLE 16 VERTEX PHARMACEUTICALS INC.: OFFERINGS 80
TABLE 17 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 80
TABLE 18 VERTEX PHARMACEUTICALS: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT 84
TABLE 19 BOEHRINGER INGELHEIM GMBH: OVERVIEW 86
TABLE 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 88
TABLE 21 GILEAD SCIENCES INC.: OVERVIEW 89
TABLE 22 BAYER AG: OVERVIEW 91
TABLE 23 BAYER AG: RECENT DEVELOPMENTS 91
TABLE 24 PFIZER INC. OVERVIEW 93
TABLE 25 PFIZER INC.: RECENT DEVELOPMENTS 93
TABLE 26 BRISTOL-MYERS SQUIBB CO.: OVERVIEW 95
TABLE 27 BRISTOL-MYERS SQUIBB CO.: KEY DEVELOPMENTS 95
TABLE 28 MERCK & CO.: OVERVIEW 97
TABLE 29 MERCK & CO.: RECENT DEVELOPMENTS 97
TABLE 30 SANOFI: OVERVIEW 99
TABLE 31 SANOFI: RECENT DEVELOPMENTS 99
TABLE 32 MALLINCKRODT PLC: OVERVIEW 100
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.